One of the four defendant Chinese companies has filed a proposed settlement in U.S. District Court in Brooklyn to resolve In re: Vitamin C Antitrust Litigation. The lawsuit, brought by commercial buyers of vitamin C, alleges that the companies formed a cartel to raise prices by limiting exports. The settlement calls for Aland Nutraceutical Co. (formerly Jiangsu Jiangshuan) to pay $9.5 million to direct purchasers, and $1 million to indirect purchasers.
Judge Brian Cogan had rejected the companies’ defense that the Chinese government required price coordination in September.
Full content: Reuters
Related content: Public Vs. Private Enforcement of Antitrust Law: A Survey
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Clifford Chance Expands Global Antitrust Team with New Partner
Dec 6, 2024 by
CPI
Spain’s Financial Regulator Awaits Antitrust Decision on BBVA’s Hostile Bid for Sabadell
Dec 5, 2024 by
CPI
RealPage Seeks Dismissal of DOJ Antitrust Suit, Citing Legal Flaws
Dec 5, 2024 by
CPI
EU Competition Chief Signals Potential Google Breakup Amid Big Tech Scrutiny
Dec 5, 2024 by
CPI
Turkey Closes Antitrust Probe into Meta’s Threads-Instagram Practices
Dec 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI
Assessing the Potential for Antitrust Moats and Trenches in the Generative AI Industry
Nov 29, 2024 by
Allison Holt, Sushrut Jain & Ashley Zhou
How SEP Hold-up Can Lead to Entrenchment
Nov 29, 2024 by
Jay Jurata, Elena Kamenir & Christie Boyden
The Role of Moats in Unlocking Economic Growth
Nov 29, 2024 by
CPI
Overcoming Moats and Entrenchment: Disruptive Innovation in Generative AI May Be More Successful than Regulation
Nov 29, 2024 by
Simon Chisholm & Charlie Whitehead